Țară: Canada
Limbă: engleză
Sursă: Health Canada
RANITIDINE (RANITIDINE HYDROCHLORIDE)
LABORATOIRE RIVA INC.
A02BA02
RANITIDINE
300MG
TABLET
RANITIDINE (RANITIDINE HYDROCHLORIDE) 300MG
ORAL
30/100
Prescription
HISTAMINE H2-ANTAGONISTS
Active ingredient group (AIG) number: 0115150001; AHFS:
CANCELLED POST MARKET
2020-09-03
PRODUCT MONOGRAPH PR RIVA-RANITIDINE Ranitidine Tablets, USP 150 mg and 300 mg HISTAMINE H 2 -RECEPTOR ANTAGONIST LABORATOIRE RIVA INC. 660 Boul. Industriel DATE OF REVISION: February 3, 2017 Blainville, Quebec J7C 3V4 www.labriva.com Control No.: 201549 66 _RIVA-RANITIDINE Product Monograph Page 2 of 27 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................................. 3 SUMMARY PRODUCT INFORMATION ............................................................................ 3 INDICATIONS AND CLINICAL USE .................................................................................. 3 CONTRAINDICATIONS ....................................................................................................... 4 WARNINGS AND PRECAUTIONS ...................................................................................... 4 ADVERSE REACTIONS........................................................................................................ 6 DRUG INTERACTIONS ........................................................................................................ 7 DOSAGE AND ADMINISTRATION .................................................................................... 8 OVERDOSAGE .................................................................................................................... 10 ACTION AND CLINICAL PHARMACOLOGY ................................................................ 10 STORAGE AND STABILITY .............................................................................................. 12 DOSAGE FORMS, COMPOSITION AND PACKAGING ................................................. 12 PART II: SCIENTIFIC INFORMATION .................................................................................... 13 PHARMACEUTICAL INFORMATION.............................................................................. 13 CLINICAL TRIALS ............................................................................................................ Citiți documentul complet